Originally published as JCO Early Release 10.1200/JCO.2005.04.0063 on October 31 2005
Journal of Clinical Oncology, Vol 23, No 33 (November 20), 2005: pp. 8512-8519
© 2005 American Society of Clinical Oncology.
Colorectal Cancer Surveillance: 2005 Update of an American Society of Clinical Oncology Practice Guideline
Christopher E. Desch,
Al B. Benson, III,
Mark R. Somerfield,
Patrick J. Flynn,
Carol Krause,
Charles L. Loprinzi,
Bruce D. Minsky,
David G. Pfister,
Katherine S. Virgo,
Nicholas J. Petrelli for the American Society of Clinical Oncology
From the American Society of Clinical Oncology, Alexandria, VA
Address reprint requests to Mark R. Somerfield, American Society of Clinical Oncology, 1900 Duke St, Suite 200, Alexandria, VA 22314; e-mail: guidelines{at}asco.org
PURPOSE: To update the 2000 American Society of Clinical Oncology guideline on colorectal cancer surveillance.
RECOMMENDATIONS: Based on results from three independently reported meta-analyses of randomized controlled trials that compared low-intensity and high-intensity programs of colorectal cancer surveillance, and on recent analyses of data from major clinical trials in colon and rectal cancer, the Panel recommends annual computed tomography (CT) of the chest and abdomen for 3 years after primary therapy for patients who are at higher risk of recurrence and who could be candidates for curative-intent surgery; pelvic CT scan for rectal cancer surveillance, especially for patients with several poor prognostic factors, including those who have not been treated with radiation; colonoscopy at 3 years after operative treatment, and, if results are normal, every 5 years thereafter; flexible proctosigmoidoscopy every 6 months for 5 years for rectal cancer patients who have not been treated with pelvic radiation; history and physical examination every 3 to 6 months for the first 3 years, every 6 months during years 4 and 5, and subsequently at the discretion of the physician; and carcinoembryonic antigen every 3 months postoperatively for at least 3 years after diagnosis, if the patient is a candidate for surgery or systemic therapy. Chest x-rays, CBCs, and liver function tests are not recommended, and molecular or cellular markers should not influence the surveillance strategy based on available evidence.
Approved by the Board on August 9, 2005.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
H. J. Murff, N. B. Peterson, J. H. Fowke, M. Hargreaves, L. B. Signorello, R. S. Dittus, W. Zheng, and W. J. Blot
Colonoscopy Screening in African Americans and Whites With Affected First-Degree Relatives
Arch Intern Med,
March 24, 2008;
168(6):
625 - 631.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. F. Snyder, C. C. Earle, R. J. Herbert, B. A. Neville, A. L. Blackford, and K. D. Frick
Preventive Care for Colorectal Cancer Survivors: A 5-Year Longitudinal Study
J. Clin. Oncol.,
March 1, 2008;
26(7):
1073 - 1079.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Lynch
New Issues in Genetic Counseling of Hereditary Colon Cancer
Clin. Cancer Res.,
November 15, 2007;
13(22):
6857s - 6861s.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sezeur, F.P. Chatelet, Ch. Cywiner, Cl. de Labriolle-Vaylet, C. Chastang, Cl. Billotey, M. Malafosse, D. Gallot, P. Betton, F. Montravers, et al.
Pathology Underrates Colon Cancer Extranodal and Nodal Metastases; Ex vivo Radioimmunodetection Helps Staging
Clin. Cancer Res.,
September 15, 2007;
13(18):
5592s - 5597s.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. J. Choi, S. H. Park, S. S. Lee, E. K. Choi, C. S. Yu, H. C. Kim, and J. C. Kim
CT Colonography for Follow-Up After Surgery for Colorectal Cancer
Am. J. Roentgenol.,
August 1, 2007;
189(2):
283 - 289.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. B. Benson III
The Hope for Today--The Promise for Tomorrow: Will Oncologists Meet the Challenge?
J. Clin. Oncol.,
June 1, 2007;
25(16):
2156 - 2158.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Gillams
Minimally invasive treatment for liver and lung metastases in colorectal cancer
BMJ,
May 19, 2007;
334(7602):
1056 - 1057.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Flamini, L. Mercatali, O. Nanni, D. Calistri, R. Nunziatini, W. Zoli, P. Rosetti, N. Gardini, A. Lattuneddu, G. M. Verdecchia, et al.
Free DNA and Carcinoembryonic Antigen Serum Levels: An Important Combination for Diagnosis of Colorectal Cancer
Clin. Cancer Res.,
December 1, 2006;
12(23):
6985 - 6988.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Earle
Failing to Plan Is Planning to Fail: Improving the Quality of Care With Survivorship Care Plans
J. Clin. Oncol.,
November 10, 2006;
24(32):
5112 - 5116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. N. Polite, J. J. Dignam, and O. I. Olopade
Colorectal Cancer Model of Health Disparities: Understanding Mortality Differences in Minority Populations
J. Clin. Oncol.,
May 10, 2006;
24(14):
2179 - 2187.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|